Evogene (NASDAQ: EVGN) reported Q4 EPS of ($0.61), $0.20 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $2.28 million versus the consensus estimate of $650 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.